Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
83 results about "Allodynia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pain from stimuli which are not normally painful. The pain may occur other than in the area stimulated.
Apparatus and method for human algometry
An apparatus and method for performing human algometry are disclosed. They include a stimulator configured to apply electrical stimulation of variable intensity to an area of a patient's body, a monitoring device configured to measure a. level of cortical activity in one or more regions of the patient's brain, and a microprocessor connected to the stimulator and the monitoring device that is configured to correlate the intensity of the electrical stimulation with the level of activity in the one or more regions of the patient's brain and to determine at least one of a measurement of pain intensity, a measurement of a sensory detection threshold (SDT), a measurement of a drug's analgesic impact, an indication of an onset of tolerance to a drug, an indication of an onset of analgesic-induced hyperalgesia, an indication of conditions of allodynia, a measurement of dose-response characteristics of pain management drugs, and a characterization of a pain condition.
Owner:CHILDRENS NAT MEDICAL CENT
Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative
ActiveUS20080306046A1Excellent therapeutical effectIncrease capacityBiocideSenses disorderDiseaseBladder capacity
[Problem] To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and / or pain.[Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and / or pain.
Owner:AUTOBAHN THERAPEUTICS INC
Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
ActiveUS8008285B2Increase choiceReduce chronic painBiocideNervous disorderChronic Widespread PainActive agent
The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and / or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment can comprise treating, preventing, reducing, or eliminating a variety of symptoms recognized as indicative of fibromyalgia, such as chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression.
Owner:CHELSEA THERAPEUTICS
Compositions and methods for treating pain
ActiveUS20060280718A1Reduce severityReduce thrombosisBiocideNervous disorderNervous systemPost injury
In the present invention, Applicants demonstrate the effect of a biomembrane sealing agent on the development of chronic pain following tissue injury as well as acute pain in a model of acute inflammation. Applicants demonstrate the ability of this class of agents referred to as “biomembrane sealing agents” to reduce the severity of hyperalgesia and allodynia following mechanical insult to the nervous system as well as their ability to reduce acute pain in a model of acute inflammation. Applicant describes the use of injectable or depot formulations of biomembrane sealing agent(s) for prophylactic treatment such as they could be administered after the insult (i.e. post-injury or post-surgery) but before the onset of acute or chronic pain. Alternatively, biomembrane sealing agents could be used to reduce the severity of acute or chronic pain after onset.
Owner:WARSAW ORTHOPEDIC INC
Method for treating diabetic peripheral neuropathic pain
The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.
Owner:UCB SA
Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and / or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment can comprise treating, preventing, reducing, or eliminating a variety of symptoms recognized as indicative of fibromyalgia, such as chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression.
Owner:CHELSEA THERAPEUTICS
Ddr2 inhibitors for the treatment of osteoarthritis
InactiveUS20150225369A1Less side effectsImprove stabilityNervous disorderOrganic chemistryCartilage lesionDepressant
The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and / or prophylaxis of physiological and / or pathophysiological states in the triggering of which DDR2 is involved, in particular for use in the treatment and / or prophylaxis of osteoarthritis, hepatocirrhosis, traumatic cartilage injuries, pain, allodynia or hyperalgesia.
Owner:MERCK PATENT GMBH
Trp inhibitors and uses thereof
The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.
Owner:POSEIDA THERAPEUTICS INC
Method and composition for treating pain or tinnitus aureum
The present invention concerns the novel use of compounds of the Formula I: for treating allodynia as major and unique pain symptom independent of the nature of an underlying disease, but that is often related to neuropathic pain or other different types of chronic or phantom pain.
Owner:UCB SA
Formulations and Methods for Delaying Onset of Chronic Neuropathic Pain
InactiveUS20150079159A1Rapid nerve blockHigh potencyBiocideOrganic active ingredientsDosing regimenWhole body
A dosing regimen for formulations that contain a therapeutic dosage of a site 1 sodium channel blocker, where the dosing regimen provides a prolonged nerve block and is in an effective amount to delay the onset of neuropathic pain, such as hyperalgesia and / or allodynia, for at least one week, and preferably longer at the site, and preferably the region (e.g. entire limb), where the nerve block was applied. The site 1 sodium channel blocker is preferably saxitoxin (STX), preferably in combination with a corticosteroid, preferably dexamethasone. In a preferred embodiment, liposomes are included in the formulation as a controlled release system, producing prolonged duration of block without systemic toxicity. As demonstrated by the examples, encapsulating STX in a controlled release system, such as liposomes, preferably also including a corticosteroid, and administering in suitable dosing regimen to achieve a prolonged nerve block without systemic toxicity, delays the onset of hyperalgesia.
Owner:CHILDRENS MEDICAL CENT CORP
Apparatus and method for human algometry
Owner:CHILDRENS NAT MEDICAL CENT
Device and method for assessing operant facial pain
InactiveUS20100331722A1Increase experienceImprove processingSurgeryAnimal housingOrofacial painFacial region
The subject invention concerns a method and device for assessing facial pain sensitivity exhibited by an animal. The device and method can be used, for example, to evaluate the effect of a disease state, drug, or other intervention, on facial pain sensitivity, such as orofacial pain sensitivity. In one embodiment, the device and method provide a way of assessing both heat and cold sensitivity (hyperalgesia and allodynia) in the facial region in a non-invasive manner. Additionally, since the animals can be kept unrestrained, there are less confounding factors such as stress, which are inherent to other facial pain testing techniques.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Uses Thereof
The present invention is directed to compounds of formula (I) wherein variables X1, X2, Y, R1a, R1b, R2a, R2b, A1, A2, A3, and A4 are as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.
Owner:ABBVIE INC
Genetically Modified Rat Models for Pain
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allo dynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use. In another aspect, the present invention provides a method of identifying a compound useful for the treatment or prevention of pain.
Owner:TRANSPOSAGEN BIOPHARM
Use of compounds active on the sigma receptor for the treatment of allodynia
The present invention refers to the use of compounds active on the sigma receptor for the treatment of allodynia.
Owner:LAB DR ESTEVE
Application of echinacoside in preparation of medicine for treating neuropathic pain
ActiveCN112494505AAlleviation of mechanical hyperalgesiaImprove sciatic nerveOrganic active ingredientsNervous disorderCompression injuryPharmaceutical drug
The invention discloses an application of echinacoside (ECH) in preparation of a medicine for treating neuropathic pain. Experimental results show that when the ECH is used in a safe dosage range, theECH with the dosage of 200 mg / kg can remarkably relieve allodynia and hyperalgesia induced by a sciatic nerve chronic compression injury model, improve histopathological changes of sciatic nerves andregulate protein expression of inflammatory cytokines; and it is proved that the ECH has the effects of relieving the neuropathic pain caused by chronic compression injury and promoting the neural functional recovery.
Owner:NINGXIA MEDICAL UNIV
Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
ActiveUS20150148296A1Effective prophylacticEffective therapeutic treatmentOrganic active ingredientsNervous disorderPeripheral neuropathic painAnticarcinogen
A medicament effective for prophylactic and / or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.
Owner:KINKI UNIVERSITY +1
Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases
The invention encompasses a method for treating a disease or condition mediated by the human MRG-X1 receptor, such as nociception, hyperalgesia, allodynia, pain related to central hypersensitivity conditions, somatic pain, visceral pain, acute pain, chronic pain, post-operative pain, headache, inflammatory pain, neurological pain, musculoskeletal pain, cancer related pain or vascular pain, in a human patient in need thereof comprising administering to the patient a therapeutically effective amount of a 3-substituted-2-(diphenylmethy)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof. The invention is also directed to the use of these compounds as molecular tools to directly explore the role of the MRG-X1 receptor in pain perception.
![Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases](https://images-eureka.patsnap.com/patent_img/894fab05-94a2-4585-ab84-f88256353dfb/US20080027095A1-20080131-D00000.png "Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases")
![Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases](https://images-eureka.patsnap.com/patent_img/894fab05-94a2-4585-ab84-f88256353dfb/US20080027095A1-20080131-D00001.png "Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases")
![Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases](https://images-eureka.patsnap.com/patent_img/894fab05-94a2-4585-ab84-f88256353dfb/US20080027095A1-20080131-D00002.png "Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases")
Owner:MERCK SHARP & DOHME CORP
Pyrazole inhibitors of cox-2 and seh
The present invention provides compounds and compositions, e.g., a series of compounds wherein a 1,5-biarylpyrazole group is conjugated to a urea group by a non-cleavable covalent chain, that are useful as dual COX-2 / sEH inhibitors. The compounds disclosed herein have activity associated with the arachidonate cascade. The activity of these compounds was demonstrated using a lipopolysaccharide (LPS) induced model of pain in the rat. The compounds of the present invention demonstrated superior anti-allodynic activity as compared to the same dose of celecoxib, i.e., a COX-2 inhibitor, also as compared to the same dose of t-AUCB, i.e., a sEH inhibitor, and also as compared to the co-administered same dose of both celecoxib and t-AUCB. The dual inhibitors of the present invention demonstrate enhanced in vivo anti-allodynic activity in a nociceptive behavioral assay. In addition, the compounds of the present invention also demonstrated to have potent anti-angiogenic effects toward endothelial cells (HUVEC) and inhibit angiogenesis in vitro, ex vivo and in vivo. The dual inhibitors of the present invention also demonstrate anti-angiogenic effect to slow breast tumor growth in vivo.
Owner:RGT UNIV OF CALIFORNIA
Combinations of Opioid/TLR4 Antagonist and a Cyclooxygenase (COX) Inhibitor for Use in the Treatment of Pain
ActiveUS20140275142A1Enhances pain treatment effectBiocideAnimal repellantsOpioid antagonistTreatment pain
Disclosed are compositions for treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4) and the second compound is a cyclooxygenase (COX) inhibitor that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone. Examples of cyclooxygenase inhibitors include ibuprofen, naproxen, meloxicam, diclofenac and meclofenamic acid, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic pain and nociceptive pain with an allodynic component.
Owner:ALLODYNIC THERAPEUTICS
Finger allodynia device based on tabletop
InactiveCN101593021ALow costSimple and compact structureInput/output for user-computer interactionGraph readingPositive pressureEngineering
The invention relates to a finger allodynia device based on a tabletop and belongs to the field of robots. The device can directly acquire three rotating angles of a knuckle of people through a potentiometer, sense the positive pressure of a finger tip when a virtual hand grabs an object through a force feedback mechanism of a direct current motor, and sense the roughness of material touched by the finger tip through a force feedback mechanism of a sucker-type electromagnet or electrorheological liquid. The device is based on the tabletop without loading on hands of people, has comfortable and intuitionistic operation, and has the advantages of simple structure and the like, and can be used in a virtual reality system.
Owner:NANJING UNIV OF AERONAUTICS & ASTRONAUTICS
Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
ActiveUS9205081B2Enhances pain treatment effectOrganic active ingredientsOpioid antagonistTherapeutic effect
Disclosed are compositions for treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4) and the second compound is a cyclooxygenase (COX) inhibitor that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone. Examples of cyclooxygenase inhibitors include ibuprofen, naproxen, meloxicam, diclofenac and meclofenamic acid, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic pain and nociceptive pain with an allodynic component.
Owner:ALLODYNIC THERAPEUTICS
Novel preventive and/or therapeutic agent for neuropathic pain
InactiveUS20100087439A1Prevent goodExcellent therapeutic agentOrganic active ingredientsNervous disorderLeg painFibromyalgia
The present invention relates to an agent for preventing and / or treating neuropathic pain comprising a 2-[(substituted-inden-7-yloxy)methyl]morpholine of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The invention is useful for providing an excellent agent for preventing and / or treating neuropathic pain, and particularly useful for providing an agent for preventing and / or treating allodynia, hyperalgesia, hyperesthesia, spontaneous pain, cancer pain, trigeminal neuralgia, phantom limb pain, postherpetic neuralgia, fibromyalgia, low back / leg pain, thalamic pain, entrapment (compressive) peripheral neuropathy, atypical facial pain, pain accompanying spinal cord injury, pain accompanying multiple sclerosis, pain accompanying chemotherapy-induced neuropathy, cancer pain on which an analgesic effect of a narcotic analgesic such as morphine is insufficient, pain accompanying diabetic neuropathy, and the like.
Owner:ASTELLAS PHARMA INC
Acylguanidines for treating osteoarthritis
ActiveUS20150361037A1Less side effectsImprove stabilityNervous disorderOrganic chemistryCartilage lesionAcyl group
The present invention relates to compounds of the formula (I) and in particular to medicaments comprising at least one compound of the formula I for use in the treatment and / or prophylaxis of physiological and / or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and / or prophylaxis of osteoarthritis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
Owner:MERCK PATENT GMBH
Open type earphone
InactiveCN101521839AAvoid damageAvoid deformationEarpiece/earphone attachmentsEar AuricleAuditory system
The invention provides an open type earphone which maintains listening models of the traditional earphone (comprising head band type, ear hanging type and back hanging type) by pressing auricles and can convert the listening model by pressing auricles into an open model by pressing cheeks; or only designs the listening model by pressing cheeks without pressing auricles. The new listening model can reduce damage to auditory system caused by pressing auricles, thereby avoiding auricles deformation, uncomfortable and tinny allodynia caused by the traditional earphone in the listening process. In addition, the new listening model also uses the capacity of auricles to collect voice apperceive, provides relatively comfortable and natural listening choice, and creates relatively open and natural listening environment for the users.
Owner:魏大宝
Pyrrolidine analogue for preventing neurogenic pain and method for production thereof
InactiveUS7968733B2Readily and massively producedFacilitate functioningNervous disorderOrganic chemistryPyrrolidineNeurogenic pain
To provide a pyrrolidine analogue having an inhibitory activity on the induction of allodynia, a method for producing the pyrrolidine analogue, and an agent for preventing a neurogenic pain.A pyrrolidine analogue which is a compound represented by the general formula (I) [wherein HOOC-φ represents an aromatic substituent having at least one carboxy group attached to the benzene ring] or a salt or ester of the compound. The compound has a potent inhibitory effect on the induction of allodynia.
Owner:HAMAMATSU PHOTONICS KK
Pyrazole inhibitors of COX-2 and sEH
The present invention provides compounds and compositions, e.g., a series of compounds wherein a 1,5-biarylpyrazole group is conjugated to a urea group by a non-cleavable covalent chain, that are useful as dual COX-2 / sEH inhibitors. The compounds disclosed herein have activity associated with the arachidonate cascade. The activity of these compounds was demonstrated using a lipopolysaccharide (LPS) induced model of pain in the rat. The compounds of the present invention demonstrated superior anti-allodynic activity as compared to the same dose of celecoxib, i.e., a COX-2 inhibitor, also as compared to the same dose of t-AUCB, i.e., a sEH inhibitor, and also as compared to the co-administered same dose of both celecoxib and t-AUCB. The dual inhibitors of the present invention demonstrate enhanced in vivo anti-allodynic activity in a nociceptive behavioral assay. In addition, the compounds of the present invention also demonstrated to have potent anti-angiogenic effects toward endothelial cells (HUVEC) and inhibit angiogenesis in vitro, ex vivo and in vivo. The dual inhibitors of the present invention also demonstrate anti-angiogenic effect to slow breast tumor growth in vivo.
Owner:RGT UNIV OF CALIFORNIA
Methods for delivery of siRNA to the spinal cord and therapies arising therefrom
ActiveUS8901097B2Prevents allodyniaSuppress painAntibacterial agentsOrganic active ingredientsUltrasound attenuationSmall interfering RNA
The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the application discloses methods to deliver an siRNA compound locally, directly and without the need for transduction vehicles and formulations in effective doses to the injured spinal cord to promote recovery of CNS function and or attenuation of allodynia.
Owner:RUTGERS THE STATE UNIV +1
Hydroxy-ethylene derivatives for the treatment of arthrosis
InactiveUS20160145297A1Lowering of ground state energyReduction in rate in rate-limiting bond breakageNervous disorderCarbamic acid derivatives preparationCartilage injuryMedicine
The present invention relates to compounds of the formula I and in particular medicaments comprising at least one compound of the formula I for use in the treatment and / or prophylaxis of physiological and / or pathophysiological conditions in the triggering of which cathepsin D is involved, in particular for use in the treatment and / or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
Owner:MERCK PATENT GMBH
Aminostatin derivatives for the treatment of arthrosis
ActiveUS20130316955A1Enhanced inhibitory effectLess side effectsNervous disorderDipeptide ingredientsCartilage injuryMedicine
The present invention relates to compounds of the formula (I) and in particular medicaments comprising at least one compound of the formula (I) for use in the treatment and / or prophylaxis of physiological and / or pathophysiological states in the triggering of which cathepsin D is involved, in particular for use in the treatment and / or prophylaxis of arthrosis, traumatic cartilage injuries, arthritis, pain, allodynia or hyperalgesia.
Owner:MERCK PATENT GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com